PT1383489E - Compostos carbamato para utilização na prevenção ou tratamento de distúrbios neurodegenerativos - Google Patents

Compostos carbamato para utilização na prevenção ou tratamento de distúrbios neurodegenerativos Download PDF

Info

Publication number
PT1383489E
PT1383489E PT02714977T PT02714977T PT1383489E PT 1383489 E PT1383489 E PT 1383489E PT 02714977 T PT02714977 T PT 02714977T PT 02714977 T PT02714977 T PT 02714977T PT 1383489 E PT1383489 E PT 1383489E
Authority
PT
Portugal
Prior art keywords
formula
disease
neurodegenerative disorders
group
acute
Prior art date
Application number
PT02714977T
Other languages
English (en)
Portuguese (pt)
Inventor
Carlos R Plata-Salaman
Boyu Zhao
Roy E Twyman
Original Assignee
Ortho Mcneil Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc
Publication of PT1383489E publication Critical patent/PT1383489E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
PT02714977T 2001-02-27 2002-02-21 Compostos carbamato para utilização na prevenção ou tratamento de distúrbios neurodegenerativos PT1383489E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27168201P 2001-02-27 2001-02-27
US10/081,764 US20020165273A1 (en) 2001-02-27 2002-02-21 Carbamate compounds for use in preventing or treating neurodegenerative disorders

Publications (1)

Publication Number Publication Date
PT1383489E true PT1383489E (pt) 2007-06-21

Family

ID=26765943

Family Applications (1)

Application Number Title Priority Date Filing Date
PT02714977T PT1383489E (pt) 2001-02-27 2002-02-21 Compostos carbamato para utilização na prevenção ou tratamento de distúrbios neurodegenerativos

Country Status (26)

Country Link
US (3) US20020165273A1 (enExample)
EP (1) EP1383489B1 (enExample)
JP (1) JP4276840B2 (enExample)
KR (1) KR100910928B1 (enExample)
CN (1) CN1235579C (enExample)
AR (1) AR035756A1 (enExample)
AT (1) ATE361745T1 (enExample)
BR (1) BR0207645A (enExample)
CA (1) CA2439295C (enExample)
CY (1) CY1106753T1 (enExample)
CZ (1) CZ301203B6 (enExample)
DE (1) DE60220043T2 (enExample)
DK (1) DK1383489T3 (enExample)
ES (1) ES2284845T3 (enExample)
HU (1) HUP0303264A3 (enExample)
IL (2) IL157591A0 (enExample)
MX (1) MXPA03007718A (enExample)
MY (1) MY138156A (enExample)
NO (1) NO20033798L (enExample)
NZ (1) NZ527990A (enExample)
PL (1) PL364680A1 (enExample)
PT (1) PT1383489E (enExample)
RS (1) RS51055B (enExample)
RU (1) RU2300373C2 (enExample)
TW (1) TWI312679B (enExample)
WO (1) WO2002067925A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2583087C (en) * 2003-09-19 2012-07-10 Galileo Pharmaceuticals, Inc. Chroman derivatives
DK1809273T3 (da) * 2004-09-16 2010-08-02 Janssen Pharmaceutica Nv Anvendelse af 2-phenyl-1,2-ethandiol-(di)carbamater til behandling af epileptogenese
MX2007004491A (es) * 2004-10-15 2007-08-08 Johnson & Johnson Compuestos de carbamato para utilizar en el tratamiento de padecimientos neurodegenerativos.
US20070021500A1 (en) * 2005-07-12 2007-01-25 Twyman Roy E Methods for neuroprotection
ES2385087T3 (es) * 2005-07-26 2012-07-18 Sk Biopharmaceuticals Co., Ltd Procedimientos para tratar trastornos relacionados con sustancias
US7632963B2 (en) * 2006-10-06 2009-12-15 Janssen Pharmaceutica Nv Crystal of (S)-(+)-2-(2-chlorophenyl)-2-hydroxy-ethyl carbamate
JP2010508355A (ja) * 2006-10-30 2010-03-18 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 鬱病を処置する方法
EA200970435A1 (ru) * 2006-10-31 2009-10-30 Янссен Фармацевтика, Н. В. Лечение общих расстройств развития
KR101532823B1 (ko) * 2010-07-02 2015-07-03 (주)바이오팜솔루션즈 페닐 카바메이트 화합물 및 이를 포함하는 근육 이완제
US9018253B2 (en) 2010-07-02 2015-04-28 Bio-Pharm Solutions Co., Ltd. Phenylcarbamate compound and muscle relaxant containing the same
US8609849B1 (en) 2010-11-30 2013-12-17 Fox Chase Chemical Diversity Center, Inc. Hydroxylated sulfamides exhibiting neuroprotective action and their method of use
US20130060024A1 (en) * 2011-09-07 2013-03-07 Satori Pharmaceuticals, Inc. Compounds useful for treating neurodegenerative disorders
EP2797878B1 (en) 2011-12-27 2017-08-16 Bio-Pharm Solutions Co., Ltd. Phenyl carbamate compounds for use in preventing or treating stroke
CN105189450B (zh) * 2013-03-12 2019-09-13 比皮艾思药物研发有限公司 氨基甲酸苯酯化合物及包含该化合物的用于预防或治疗精神障碍的组合物
ES2998534T3 (en) * 2013-03-12 2025-02-20 Bio Pharm Solutions Co Ltd Phenyl carbamate compounds for use in preventing or treating pediatric epilesy
WO2017150903A1 (en) 2016-02-29 2017-09-08 Bio-Pharm Solutions Co., Ltd. Sulfamate derivative compounds, processes for preparing them and their uses
KR102635936B1 (ko) 2016-12-14 2024-02-13 에스케이바이오팜 주식회사 탈수초성 질환의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도
JP7408643B2 (ja) * 2018-09-21 2024-01-05 エスケー バイオファーマスティカルズ カンパニー リミテッド カルバメート化合物及びそれを含む製剤の急性ストレス障害又は心的外傷後ストレス障害の予防、軽減又は治療のための使用
EP4204395A4 (en) * 2020-08-31 2024-08-07 Bio-Pharm Solutions Co., Ltd. Phenyl alkyl carbamate compounds for use in preventing or treating neurodegenerative disease
EP4211125A4 (en) 2020-09-10 2024-10-02 Bio-Pharm Solutions Co., Ltd. SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING A PSYCHIATRIC DISORDER

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3313692A (en) * 1958-04-21 1967-04-11 Armour Pharma Method of inducing calming and muscle relaxation with carbamates
US3278380A (en) * 1962-02-06 1966-10-11 Armour Pharma Methods of calming employing diphenyl hydroxy carbamate compounds
US3265728A (en) * 1962-07-18 1966-08-09 Armour Pharma Substituted phenethyl carbamates
US5474990A (en) * 1989-10-20 1995-12-12 Olney; John W. Barbiturates as safening agents in conjunction with NMDA antagonists
CN1109880A (zh) * 1994-02-03 1995-10-11 合成实验室公司 3-(2-氨基乙基)-4-[3-(三氟甲基)苯甲酰基]-3，4-二氢-2h-1，4-苯并噁嗪衍生物、制备及其应用
US5492930A (en) * 1994-04-25 1996-02-20 Schering Corporation Method and formulation for treating CNS disorders
US5698588A (en) * 1996-01-16 1997-12-16 Yukong Limited Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol
US5728728A (en) * 1996-04-10 1998-03-17 Kozachuk; Walter E. Methods of providing neuroprotection
US6232434B1 (en) * 1996-08-02 2001-05-15 Duke University Medical Center Polymers for delivering nitric oxide in vivo
PT1401424E (pt) * 2001-02-27 2007-02-28 Ortho Mcneil Pharm Inc Compostos carbamato para utilização na prevenção ou tratamento de distúrbios psicóticos
JP2004527492A (ja) * 2001-02-27 2004-09-09 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 運動障害の予防もしくは治療における使用のためのカルバメート化合物
CA2439475C (en) * 2001-02-27 2010-05-18 Carlos R. Plata-Salaman Carbamate compounds for use in preventing or treating bipolar disorder

Also Published As

Publication number Publication date
RS67403A (sr) 2006-12-15
PL364680A1 (en) 2004-12-13
IL157591A (en) 2009-12-24
CA2439295C (en) 2010-05-25
HK1060516A1 (en) 2004-08-13
CZ301203B6 (cs) 2009-12-09
JP2004523555A (ja) 2004-08-05
BR0207645A (pt) 2004-12-28
MXPA03007718A (es) 2004-11-12
DE60220043D1 (de) 2007-06-21
IL157591A0 (en) 2004-03-28
RU2300373C2 (ru) 2007-06-10
CN1235579C (zh) 2006-01-11
HK1065486A1 (en) 2005-02-25
EP1383489B1 (en) 2007-05-09
JP4276840B2 (ja) 2009-06-10
CZ20032313A3 (cs) 2004-08-18
HUP0303264A3 (en) 2012-07-30
EP1383489A1 (en) 2004-01-28
HUP0303264A2 (hu) 2004-01-28
AR035756A1 (es) 2004-07-07
WO2002067925A1 (en) 2002-09-06
DE60220043T2 (de) 2008-01-10
KR100910928B1 (ko) 2009-08-06
US20040171679A1 (en) 2004-09-02
CY1106753T1 (el) 2012-05-23
NO20033798D0 (no) 2003-08-26
NO20033798L (no) 2003-09-26
CA2439295A1 (en) 2002-09-06
NZ527990A (en) 2006-01-27
CN1503667A (zh) 2004-06-09
RS51055B (sr) 2010-10-31
RU2003128982A (ru) 2005-03-10
MY138156A (en) 2009-04-30
DK1383489T3 (da) 2007-08-06
US20020165273A1 (en) 2002-11-07
US20090005442A1 (en) 2009-01-01
TWI312679B (en) 2009-08-01
KR20030076714A (ko) 2003-09-26
ATE361745T1 (de) 2007-06-15
ES2284845T3 (es) 2007-11-16

Similar Documents

Publication Publication Date Title
US20090005442A1 (en) Carbamate compounds for use in preventing or treating neurodegenerative disorders
JP4276839B2 (ja) 双極性障害の予防もしくは治療における使用のためのカルバメート化合物
CN101287459A (zh) 用于治疗神经变性性疾病的氨基甲酸酯化合物
CA2439475C (en) Carbamate compounds for use in preventing or treating bipolar disorder
AU2002242296B2 (en) Carbamate compounds for use in preventing or treating psychotic disorders
AU2002242296A1 (en) Carbamate compounds for use in preventing or treating psychotic disorders
SK1962003A3 (en) Carbamate compounds for use in preventing or treating neuropathic pain and cluster and migraine headache-associated pain
AU2002247203B2 (en) Carbamate compounds for use in preventing or treating neurodegenerative disordrers
MX2007004491A (es) Compuestos de carbamato para utilizar en el tratamiento de padecimientos neurodegenerativos.
AU2002247203A1 (en) Carbamate compounds for use in preventing or treating neurodegenerative disordrers
HK1060516B (en) Carbamate compounds for use in preventing or treating neurodegenerative disorders
ES2327721T3 (es) Compuestos de carbamato para uso en la prevencion o tratamiento del dolor neuropatico.
CA2454047C (en) Carbamate compounds for use in preventing or treating neuropathic pain and cluster and migraine headache-associated pain
HK1063435B (en) Carbamate compounds for use in preventing or treating neuropathic pain